This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Oncology, Nuclear medicine, PET-CT, Biopsy, Sampling, Tissue characterisation, Neoplasia
Authors:
S. Brocchi, A. Cappelli, C. Mosconi, M. Renzulli, F. Modestino, C. Nanni, T. Balbi, S. Fanti, R. Golfieri; Bologna/IT
DOI:
10.1594/ecr2016/B-1231
Purpose
Biopsy of suspect tissues is required to reach a diagnosis and to plan adequate treatment.
Open incisional biopsy (OIB) is traditionally the method of choice,
providing an accuracy of approximately 100%.
OIB is very expensive and is associated with several drawbacks [1].
The development of imaging-guided biopsies (US,
CT) has almost overcome these disadvantages.
However recent literature shows that imaging-guided biopsies have an accuracy between 70-90%,
with several non-diagnostic procedures [2].
FDG PET/CT is a functional imaging technique that highlights,
with a very high sensitivity,
areas of active metabolism; it detects abnormal signals even before cancer-related morphological changes occur,
and can accurately discriminate between fibrous residual tissue after therapy and disease persistence or relapse [3,
4].
It can potentially be used to drive the biopsy to the most active area within a suspect malignant mass.
A recent review of the literature underlines the role of PET/CT as an imaging method of choice for guiding biopsy procedures [5].
Aim of this study is to preliminary assess the feasibility and accuracy of real-time FDG PET/CT guided biopsy in the diagnosis of malignancy.